A conditionally replication-defective cytomegalovirus vaccine elicits potent and diverse functional monoclonal antibodies in a phase I clinical trial

A conditionally replication-defective human cytomegalovirus (HCMV) vaccine, V160, was shown to be safe and immunogenic in a two-part, double-blind, randomized, placebo-controlled phase I clinical trial (NCT01986010). However, the specificities and functional properties of V160-elicited antibodies re...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Leike, Freed, Daniel C., Liu, Yaping, Li, Fengsheng, Barrett, Diane F., Xiong, Wei, Ye, Xiaohua, Adler, Stuart P., Rupp, Richard E., Wang, Dai, Zhang, Ningyan, Fu, Tong-Ming, An, Zhiqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172929/
https://www.ncbi.nlm.nih.gov/pubmed/34078915
http://dx.doi.org/10.1038/s41541-021-00342-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172929/
https://www.ncbi.nlm.nih.gov/pubmed/34078915
http://dx.doi.org/10.1038/s41541-021-00342-3

Ejemplares similares